Published in Clin Microbiol Rev on October 01, 2004
Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol (2008) 1.82
Rapid and sensitive detection of Shiga toxin-producing Escherichia coli from nonenriched stool specimens by real-time PCR in comparison to enzyme immunoassay and culture. J Clin Microbiol (2009) 1.69
Bacterial effector binding to ribosomal protein s3 subverts NF-kappaB function. PLoS Pathog (2009) 1.61
Shiga toxin-producing Escherichia coli O104:H4: a new challenge for microbiology. Appl Environ Microbiol (2012) 1.39
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
Immunoglobulin A antibodies against ricin A and B subunits protect epithelial cells from ricin intoxication. Infect Immun (2006) 1.32
Passive protection against anthrax by using a high-affinity antitoxin antibody fragment lacking an Fc region. Infect Immun (2005) 1.28
Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect Immun (2008) 1.26
Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody. Infect Immun (2008) 1.19
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis (2009) 0.98
Functional differences and interactions between the Escherichia coli type III secretion system effectors NleH1 and NleH2. Infect Immun (2012) 0.97
Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother (2009) 0.95
The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics (2009) 0.94
The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun (2006) 0.94
Evaluation of Fab and F(ab')2 fragments and isotype variants of a recombinant human monoclonal antibody against Shiga toxin 2. Infect Immun (2010) 0.91
New high-affinity monoclonal antibodies against Shiga toxin 1 facilitate the detection of hybrid Stx1/Stx2 in vivo. PLoS One (2014) 0.91
A neutralizing antibody to the a chain of abrin inhibits abrin toxicity both in vitro and in vivo. Clin Vaccine Immunol (2008) 0.91
A DNA vaccine encoding the enterohemorragic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol (2009) 0.89
Antibody-mediated inhibition of ricin toxin retrograde transport. MBio (2014) 0.89
Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun (2014) 0.89
Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect Immun (2005) 0.88
Recombinant Shiga toxin B-subunit-keyhole limpet hemocyanin conjugate vaccine protects mice from Shigatoxemia. Infect Immun (2005) 0.88
Progress towards recombinant anti-infective antibodies. Recent Pat Antiinfect Drug Discov (2009) 0.88
Shiga toxin pathogenesis: kidney complications and renal failure. Curr Top Microbiol Immunol (2012) 0.86
Mouse in vivo neutralization of Escherichia coli Shiga toxin 2 with monoclonal antibodies. Toxins (Basel) (2013) 0.86
Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLoS One (2011) 0.86
In vitro and in vivo protective efficacies of antibodies that neutralize the RNA N-glycosidase activity of Shiga toxin 2. BMC Immunol (2010) 0.84
Shiga toxin 2-specific but not shiga toxin 1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing shiga toxin 1 and shiga toxin 2. J Infect Dis (2010) 0.81
Baicalin Inhibits the Lethality of Shiga-Like Toxin 2 in Mice. Antimicrob Agents Chemother (2015) 0.79
Escherichia coli virulence protein NleH1 interaction with the v-Crk sarcoma virus CT10 oncogene-like protein (CRKL) governs NleH1 inhibition of the ribosomal protein S3 (RPS3)/nuclear factor κB (NF-κB) pathway. J Biol Chem (2013) 0.79
Selective Evolution of Ligands by Exponential Enrichment to Identify RNA Aptamers against Shiga Toxins. J Nucleic Acids (2014) 0.79
Baicalin inhibits the lethality of ricin in mice by inducing protein oligomerization. J Biol Chem (2015) 0.77
Escherichia coli type III secretion system 2: a new kind of T3SS? Vet Res (2014) 0.77
Biodistribution and elimination kinetics of systemic Stx2 by the Stx2A and Stx2B subunit-specific human monoclonal antibodies in mice. BMC Immunol (2012) 0.76
Efficacy of Urtoxazumab (TMA-15 Humanized Monoclonal Antibody Specific for Shiga Toxin 2) Against Post-Diarrheal Neurological Sequelae Caused by Escherichia coli O157:H7 Infection in the Neonatal Gnotobiotic Piglet Model. Toxins (Basel) (2017) 0.75
A monoclonal antibody to an abrin chimera recognizing a unique epitope on abrin A chain confers protection from abrin-induced lethality. Hum Vaccin Immunother (2015) 0.75
Modeling neutralization of Shiga 2 toxin by A-and B-subunit-specific human monoclonal antibodies. J Biol Phys (2016) 0.75
Food-related illness and death in the United States. Emerg Infect Dis (1999) 39.22
The epidemiology of infections caused by Escherichia coli O157:H7, other enterohemorrhagic E. coli, and the associated hemolytic uremic syndrome. Epidemiol Rev (1991) 17.90
Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet (1983) 10.11
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev (1998) 8.74
Shiga-like toxin-converting phages from Escherichia coli strains that cause hemorrhagic colitis or infantile diarrhea. Science (1984) 7.94
The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med (2000) 7.78
Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis (1989) 6.49
Iron regulation of Shiga-like toxin expression in Escherichia coli is mediated by the fur locus. J Bacteriol (1987) 6.13
Cloning and sequencing of a Shiga-like toxin type II variant from Escherichia coli strain responsible for edema disease of swine. J Bacteriol (1988) 5.43
Escherichia coli harboring Shiga toxin 2 gene variants: frequency and association with clinical symptoms. J Infect Dis (2001) 5.27
Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun (1985) 5.04
[Hemolytic-uremic syndrome: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia]. Schweiz Med Wochenschr (1955) 4.90
Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA (2002) 4.72
Two copies of Shiga-like toxin II-related genes common in enterohemorrhagic Escherichia coli strains are responsible for the antigenic heterogeneity of the O157:H- strain E32511. Infect Immun (1991) 4.63
Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis (2000) 4.24
Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis (1995) 4.06
Role of a 60-megadalton plasmid and Shiga-like toxins in the pathogenesis of infection caused by enterohemorrhagic Escherichia coli O157:H7 in gnotobiotic piglets. Infect Immun (1987) 3.96
The pathogenesis of hemorrhagic colitis caused by Escherichia coli O157:H7 in gnotobiotic piglets. J Infect Dis (1986) 3.96
Cloning and nucleotide sequencing of Vero toxin 2 variant genes from Escherichia coli O91:H21 isolated from a patient with the hemolytic uremic syndrome. Microb Pathog (1990) 3.88
Pathogenesis of shigella diarrhea. XI. Isolation of a shigella toxin-binding glycolipid from rabbit jejunum and HeLa cells and its identification as globotriaosylceramide. J Exp Med (1986) 3.61
Nature and distribution of mucosal lesions associated with enteropathogenic and enterohemorrhagic Escherichia coli in piglets and the role of plasmid-mediated factors. Infect Immun (1989) 3.51
Haemolytic uraemic syndromes in the British Isles, 1985-8: association with verocytotoxin producing Escherichia coli. Part 2: Microbiological aspects. Arch Dis Child (1990) 3.51
Infection of gnotobiotic pigs with an Escherichia coli O157:H7 strain associated with an outbreak of hemorrhagic colitis. Infect Immun (1986) 3.39
Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun (1993) 3.36
Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A (2002) 3.16
The United States National Prospective Hemolytic Uremic Syndrome Study: microbiologic, serologic, clinical, and epidemiologic findings. J Infect Dis (2001) 3.14
The cytotoxic activity of Shigella toxin. Evidence for catalytic inactivation of the 60 S ribosomal subunit. J Biol Chem (1981) 3.13
Haemolytic uraemic syndromes in the British Isles 1985-8: association with verocytotoxin producing Escherichia coli. Part 1: Clinical and epidemiological aspects. Arch Dis Child (1990) 3.04
Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol (1992) 3.03
Mouse model for colonization and disease caused by enterohemorrhagic Escherichia coli O157:H7. Infect Immun (1990) 3.00
Properties of strains of Escherichia coli belonging to serogroup O157 with special reference to production of Vero cytotoxins VT1 and VT2. Epidemiol Infect (1987) 2.98
Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature (2000) 2.94
Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study. J Infect Dis (2002) 2.89
Identification of new verocytotoxin type 2 variant B-subunit genes in human and animal Escherichia coli isolates. J Clin Microbiol (1998) 2.80
Functional and genetic analysis of regulatory regions of coliphage H-19B: location of shiga-like toxin and lysis genes suggest a role for phage functions in toxin release. Mol Microbiol (1998) 2.78
Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol (1988) 2.76
A new Shiga toxin 2 variant (Stx2f) from Escherichia coli isolated from pigeons. Appl Environ Microbiol (2000) 2.72
The role of the eaeA gene in diarrhea and neurological complications in a gnotobiotic piglet model of enterohemorrhagic Escherichia coli infection. Infect Immun (1995) 2.69
Molecular cloning and nucleotide sequence of another variant of the Escherichia coli Shiga-like toxin II family. J Gen Microbiol (1990) 2.53
Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature (1994) 2.39
A new biological agent for treatment of Shiga toxigenic Escherichia coli infections and dysentery in humans. Nat Med (2000) 2.22
Pathogenesis of Shiga toxin-induced hemolytic uremic syndrome. Pediatr Nephrol (2001) 2.18
Hemolytic-uremic syndrome during an outbreak of Escherichia coli O157:H7 infections in institutions for mentally retarded persons: clinical and epidemiologic observations. J Pediatr (1990) 2.16
Non-O157:H7 Stx2-producing Escherichia coli strains associated with sporadic cases of hemolytic-uremic syndrome in adults. J Clin Microbiol (1998) 2.16
Cloning and nucleotide sequence of a variant Shiga-like toxin II gene from Escherichia coli OX3:H21 isolated from a case of sudden infant death syndrome. Microb Pathog (1992) 2.13
Regulation of the Shiga-like toxin II operon in Escherichia coli. Infect Immun (1996) 2.13
Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immun (1988) 2.12
Clinical and clinicopathologic abnormalities in greyhounds with cutaneous and renal glomerular vasculopathy: 18 cases (1992-1994) J Am Vet Med Assoc (1997) 2.12
Variants of Shiga-like toxin II constitute a major toxin component in Escherichia coli O157 strains from patients with haemolytic uraemic syndrome. J Med Microbiol (1994) 2.08
High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol (1996) 2.07
By-passing immunization: building high affinity human antibodies by chain shuffling. Biotechnology (N Y) (1992) 2.05
Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA (2003) 2.04
Therapeutic antibody fragments with prolonged in vivo half-lives. Nat Biotechnol (1999) 2.02
Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med (2002) 2.00
Coamplification and coexpression of human tissue-type plasminogen activator and murine dihydrofolate reductase sequences in Chinese hamster ovary cells. Mol Cell Biol (1985) 1.97
Role of verotoxin receptors in pathogenesis. Trends Microbiol (1996) 1.95
Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics (1997) 1.90
Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet Pathol (1991) 1.85
Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat Biotechnol (1999) 1.85
The pathogenesis and treatment of hemolytic uremic syndrome. J Am Soc Nephrol (1998) 1.83
Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis (1995) 1.81
Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr (1994) 1.72
A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis (1998) 1.68
Effect of early fosfomycin treatment on prevention of hemolytic uremic syndrome accompanying Escherichia coli O157:H7 infection. Clin Nephrol (1999) 1.68
Gnotobiotic piglets develop thrombotic microangiopathy after oral infection with enterohemorrhagic Escherichia coli. Am J Clin Pathol (2002) 1.59
Cloning and sequencing of a Shiga-like toxin II-related gene from Escherichia coli O157:H7 strain 7279. Zentralbl Bakteriol (1992) 1.56
Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr (1992) 1.56
Preparation of VT1 and VT2 hybrid toxins from their purified dissociated subunits. Evidence for B subunit modulation of a subunit function. J Biol Chem (1991) 1.53
Cerebral infection with Escherichia coli O157:H7 in humans and gnotobiotic piglets. J Clin Pathol (1988) 1.52
Sequence of a variant Shiga-like toxin type-I operon of Escherichia coli O111:H-. Gene (1993) 1.51
Isolation of Vero cytotoxin-producing Escherichia coli serotypes O9ab:H- and O101:H-carrying VT2 variant gene sequences from a patient with haemolytic uraemic syndrome. Eur J Clin Microbiol Infect Dis (1994) 1.51
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol (1995) 1.47
Verotoxin-binding in human renal sections. Nephron (1994) 1.47
Isolation and characterization of sorbitol-fermenting Shiga toxin (Verocytotoxin)-producing Escherichia coli O157:H- strains in the Czech Republic. J Clin Microbiol (1998) 1.45
Escherichia coli O157:H7 strains that express Shiga toxin (Stx) 2 alone are more neurotropic for gnotobiotic piglets than are isotypes producing only Stx1 or both Stx1 and Stx2. J Infect Dis (2000) 1.44
Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. Vet Res (1999) 1.40
Influence of RecA on in vivo virulence and Shiga toxin 2 production in Escherichia coli pathogens. Microb Pathog (1999) 1.39
Production and characterisation of monoclonal antibodies to Verotoxins 1 and 2 from Escherichia coli of serotype O 157:H7. J Med Microbiol (1989) 1.38
Antibody engineering. Annu Rev Biomed Eng (2000) 1.37
Extrarenal involvement in diarrhoea-associated haemolytic-uraemic syndrome. Pediatr Nephrol (1995) 1.26
Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem (2001) 1.24
A therapeutic agent with oriented carbohydrates for treatment of infections by Shiga toxin-producing Escherichia coli O157:H7. Proc Natl Acad Sci U S A (2002) 1.23
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J Immunol Methods (1998) 1.20
Virulence of Shiga toxin-producing Escherichia coli (STEC) in orally-infected mice correlates with the type of toxin produced by the infecting strain. Jpn J Med Sci Biol (1998) 1.20
Neurological manifestations of hemorrhagic colitis in the outbreak of Escherichia coli O157:H7 infection in Japan. Acta Paediatr (1993) 1.17
Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome. Pediatr Res (1998) 1.17
High level synthesis of immunoglobulins in Chinese hamster ovary cells. J Immunol (1990) 1.16
The common ovine Shiga toxin 2-containing Escherichia coli serotypes and human isolates of the same serotypes possess a Stx2d toxin type. J Clin Microbiol (2001) 1.16
Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis (2001) 1.15
High level expression of the humanized monoclonal antibody Campath-1H in Chinese hamster ovary cells. Biotechnology (N Y) (1991) 1.14
Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol (2002) 1.14
Escherichia coli O157:H7 causes more-severe systemic disease in suckling piglets than in colostrum-deprived neonatal piglets. Infect Immun (2000) 1.13
Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun (2003) 1.12
Isolation and characterization of functional Shiga toxin subunits and renatured holotoxin. Mol Microbiol (1989) 1.11
Solution structure of the complex between the B-subunit homopentamer of verotoxin VT-1 from Escherichia coli and the trisaccharide moiety of globotriaosylceramide. Biochemistry (1998) 1.11
Antibody-based protection of gnotobiotic piglets infected with Escherichia coli O157:H7 against systemic complications associated with Shiga toxin 2. Infect Immun (1999) 1.10
Effects of Escherichia coli Shiga-like toxins (verotoxins) in pigs. Can J Vet Res (1989) 1.09
MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet (2008) 9.00
Soluble Urokinase Receptor and Chronic Kidney Disease. N Engl J Med (2015) 4.85
APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol (2011) 4.80
Mutations in kelch-like 3 and cullin 3 cause hypertension and electrolyte abnormalities. Nature (2012) 4.26
The genome of Cryptosporidium hominis. Nature (2004) 3.93
Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol (2012) 2.83
Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int (2011) 2.43
Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol (2012) 2.42
Management of childhood onset nephrotic syndrome. Pediatrics (2009) 1.87
Urolithiasis in pediatric patients: a single center study of incidence, clinical presentation and outcome. J Urol (2007) 1.86
Recurrent focal segmental glomerulosclerosis after kidney transplantation. Pediatr Nephrol (2015) 1.73
Non-enteropathic hemolytic uremic syndrome: causes and short-term course. Am J Kidney Dis (2004) 1.71
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Critical and honest conversations: the evidence behind the "Choosing Wisely" campaign recommendations by the American Society of Nephrology. Clin J Am Soc Nephrol (2012) 1.69
Basic fibroblast growth factor among children with diarrhea-associated hemolytic uremic syndrome. J Am Soc Nephrol (2002) 1.63
Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun (2002) 1.49
A response to "Children in clinical research: a conflict of moral values" by Vera Hassner Sharav. Am J Bioeth (2003) 1.39
U.S. Preventive Services Task Force recommendation and pediatric hypertension screening: dereliction of duty or call to arms? J Clin Hypertens (Greenwich) (2014) 1.38
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int (2010) 1.38
Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun (2005) 1.38
NPHS2 variation in sporadic focal segmental glomerulosclerosis. J Am Soc Nephrol (2007) 1.36
Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol (2009) 1.36
KDOQI US commentary on the 2012 KDIGO clinical practice guideline for glomerulonephritis. Am J Kidney Dis (2013) 1.29
Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun (2002) 1.23
Variants in the Wilms' tumor gene are associated with focal segmental glomerulosclerosis in the African American population. Physiol Genomics (2005) 1.22
Management patterns of childhood-onset nephrotic syndrome. Pediatr Nephrol (2009) 1.16
Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy. Pediatr Nephrol (2002) 1.14
Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun (2003) 1.12
Increased adherence and actin pedestal formation by dam-deficient enterohaemorrhagic Escherichia coli O157:H7. Mol Microbiol (2007) 1.09
Treatment of recurrent focal segmental glomerular sclerosis posttransplant with a multimodal approach including high-galactose diet and oral galactose supplementation. Transplantation (2011) 1.08
A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun (2013) 1.06
EspFU, a type III-translocated effector of actin assembly, fosters epithelial association and late-stage intestinal colonization by E. coli O157:H7. Cell Microbiol (2007) 1.06
Assessing health status and health care utilization in adolescents with chronic kidney disease. J Am Soc Nephrol (2005) 1.05
Biomarkers of therapeutic response in primary nephrotic syndrome. Pediatr Nephrol (2012) 1.05
Clinical spectrum of gross hematuria in pediatric patients. Clin Pediatr (Phila) (2006) 1.04
Phase 1 trial of adalimumab in Focal Segmental Glomerulosclerosis (FSGS): II. Report of the FONT (Novel Therapies for Resistant FSGS) study group. Am J Kidney Dis (2009) 1.03
Bisphenol A exposure is associated with low-grade urinary albumin excretion in children of the United States. Kidney Int (2013) 1.02
Efficacy of mycophenolate mofetil in pediatric patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol (2005) 0.99
Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis (2009) 0.98
Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol (2008) 0.97
Production and characterization of monoclonal antibodies against Enterocytozoon bieneusi purified from rhesus macaques. Infect Immun (2005) 0.97
Urinary exosomal Wilms' tumor-1 as a potential biomarker for podocyte injury. Am J Physiol Renal Physiol (2013) 0.95
Renal manifestations of a mutation in the uromodulin (Tamm Horsfall protein) gene. Am J Kidney Dis (2003) 0.95
Evidence for mitochondrial-derived alternative oxidase in the apicomplexan parasite Cryptosporidium parvum: a potential anti-microbial agent target. Int J Parasitol (2004) 0.95
Focal segmental glomerulosclerosis and chronic kidney disease in pediatric patients. Adv Chronic Kidney Dis (2011) 0.94
The Shigella dysenteriae serotype 1 proteome, profiled in the host intestinal environment, reveals major metabolic modifications and increased expression of invasive proteins. Proteomics (2009) 0.94
Patient recruitment into a multicenter randomized clinical trial for kidney disease: report of the focal segmental glomerulosclerosis clinical trial (FSGS CT). Clin Transl Sci (2012) 0.92
Modulating the progression in IgA nephropathy. Nephron Clin Pract (2006) 0.92
Comparison of two label-free global quantitation methods, APEX and 2D gel electrophoresis, applied to the Shigella dysenteriae proteome. Proteome Sci (2009) 0.91
Host cell tropism underlies species restriction of human and bovine Cryptosporidium parvum genotypes. Infect Immun (2004) 0.91
Quantitative tracking of Cryptosporidium infection in cell culture with CFSE. J Parasitol (2006) 0.91
Urinary phthalates are associated with higher blood pressure in childhood. J Pediatr (2013) 0.91
Enhanced Actin Pedestal Formation by Enterohemorrhagic Escherichia coli O157:H7 Adapted to the Mammalian Host. Front Microbiol (2011) 0.90
Treatment of recurrent focal segmental glomerulosclerosis in pediatric kidney transplant recipients: effect of rituximab. J Transplant (2011) 0.90
Mycophenolate mofetil in children with frequently relapsing nephrotic syndrome: a report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol (2006) 0.90
Acute glomerulonephritis and acute kidney injury associated with 2009 influenza A:H1N1 in an infant. Pediatr Nephrol (2010) 0.89
Serial propagation of the microsporidian Enterocytozoon bieneusi of human origin in immunocompromised rodents. Infect Immun (2006) 0.89
Mutation conferring apical-targeting motif on AE1 exchanger causes autosomal dominant distal RTA. J Am Soc Nephrol (2012) 0.88
Is there clinical value in measuring suPAR levels in FSGS? Clin J Am Soc Nephrol (2013) 0.87
Autosomal dominant mutation in the signal peptide of renin in a kindred with anemia, hyperuricemia, and CKD. Am J Kidney Dis (2011) 0.86
In vivo versus in vitro protein abundance analysis of Shigella dysenteriae type 1 reveals changes in the expression of proteins involved in virulence, stress and energy metabolism. BMC Microbiol (2011) 0.86
Bile acids enhance invasiveness of Cryptosporidium spp. into cultured cells. Infect Immun (2006) 0.86
Atypical hemolytic uremic syndrome associated with H1N1 influenza A virus infection. Pediatr Nephrol (2010) 0.86
Affects of N-terminal variation in the SeM protein of Streptococcus equi on antibody and fibrinogen binding. Vaccine (2009) 0.85
Dietary phthalates and low-grade albuminuria in US children and adolescents. Clin J Am Soc Nephrol (2013) 0.85
Idiopathic membranous nephropathy in pediatric patients: presentation, response to therapy, and long-term outcome. BMC Nephrol (2007) 0.84
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group. BMC Nephrol (2010) 0.84
Meprin-alpha in chronic diabetic nephropathy: interaction with the renin-angiotensin axis. Am J Physiol Renal Physiol (2005) 0.84
Evaluation of failure to thrive: diagnostic yield of testing for renal tubular acidosis. Pediatrics (2003) 0.82
Involvement of the fractalkine pathway in the pathogenesis of childhood hemolytic uremic syndrome. Blood (2006) 0.82
Teaching bioethics: the tale of a "soft" science in a hard world. Teach Learn Med (2010) 0.81
Angiotensin converting enzyme inhibitor therapy in children with Alport syndrome: effect on urinary albumin, TGF-beta, and nitrite excretion. BMC Nephrol (2002) 0.80
Urinary tract infections, VUR, and autosomal dominant polycystic kidney disease. Pediatr Nephrol (2003) 0.80
Cisplatinum nephrotoxicity in oncology therapeutics: retrospective review of patients treated between 2005 and 2012. Pediatr Nephrol (2014) 0.80
Urinary podocyte mRNA excretion in children with D+HUS: a potential marker of long-term outcome. Ren Fail (2006) 0.79
Renal function and proteinuria after successful immunosuppressive therapies in patients with FSGS. Clin J Am Soc Nephrol (2012) 0.79
Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol (2013) 0.79
The impact of disease duration on quality of life in children with nephrotic syndrome: a Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol (2015) 0.79
Regarding Maas's editorial letter on serum suPAR levels. Kidney Int (2012) 0.78
Nitric oxide in obstructive uropathy: role of endothelial nitric oxide synthase. J Urol (2002) 0.78
Vitamin E therapy in IgA nephropathy: a double-blind, placebo-controlled study. Pediatr Nephrol (2003) 0.78
Nephrotic-range proteinuria in a child with retinoic acid syndrome. Pediatr Nephrol (2011) 0.78
Circulating factor in FSGS: a black sheep in the suPAR family? Pediatr Nephrol (2013) 0.78
Prevention of serious bacterial infections in new-onset nephrotic syndrome: a survey of current practices. Clin Pediatr (Phila) (2002) 0.77
Introduction: education teaching article series on hemolytic uremic syndrome. Pediatr Nephrol (2008) 0.77
Dysregulated chemokine receptor expression and chemokine-mediated cell trafficking in pediatric patients with ESRD. Clin J Am Soc Nephrol (2008) 0.77
Clinico-pathologic findings in medullary cystic kidney disease type 2. Pediatr Nephrol (2005) 0.77
Cardiac disease in children with primary glomerular disorders-role of focal segmental glomerulosclerosis. Pediatr Nephrol (2004) 0.77
Urinary meprin-alpha: a potential marker of diabetic nephropathy. J Pediatr Endocrinol Metab (2004) 0.76
Evaluation of pediatric patients with mild-to-moderate hypertension: yield of diagnostic testing. Pediatrics (2008) 0.76
Diagnostic yield of renal biopsies: a retrospective single center review. BMC Nephrol (2009) 0.76
Treatment of hyperuricemia in essential hypertension. Hypertension (2007) 0.75
Hydronephrosis in infants and children: natural history and risk factors for persistence in children followed by a medical service. Clin Med Pediatr (2009) 0.75
Does uncle Sam really want you? A response to "Rethinking research Ethics" by Rosamond Rhodes (AJOB 5:1). Am J Bioeth (2005) 0.75
Charles Barkley's dilemma: A response to "The professionalism movement: can we pause?" by Delese Wear and Mark G. Kuczewski (AJOB 4:2). Am J Bioeth (2004) 0.75
The secret sharer. Am J Bioeth (2006) 0.75
Facing the truth: A response to "On the ethics of facial transplantation research" by Wiggins et al. Am J Bioeth (2004) 0.75
Escherichia coli O104:H4 outbreak in Germany. N Engl J Med (2012) 0.75
IgA nephropathy: a twenty year retrospective single center experience. Clin Med Pediatr (2009) 0.75
Blind spots. Am J Bioeth (2011) 0.75